西安乐健生物科技

Xi'an Lejian Biotechnology is a pharmaceutical and biotechnology company based in Xi'an, China, specializing in the research and development of traditional Chinese medicines (TCM) and natural botanical products. Founded in 2011, the company focuses on addressing metabolic and ophthalmic conditions, particularly diabetic complications. Its lead candidate, Shenqi Pingheng Capsule (参芪平衡胶囊), entered a Phase 3 clinical trial in July 2025 for the treatment of non-proliferative diabetic retinopathy. The company's portfolio also includes Fushiming Capsule (复视明胶囊) for diabetic eye diseases and Xiandi Spray (显迪喷雾剂) for skin disorders.